Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358929 · ClinicalTrials.gov registry record · Phase 1
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT01358929 is a Phase 1 study of Diabetes Mellitus, Type 2 that has completed, run by Hoffmann-La Roche. The registered enrollment target is 45 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01358929, a Phase 1 study of Diabetes Mellitus, Type 2, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO6807952
Study Locations (2)
California
- - Chula Vista
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358929
The ClinicalTrials.gov registry entry for NCT01358929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01358929 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT01358929 about?
NCT01358929 is a clinical study titled "A Study of RO6807952 in Patients With Diabetes Mellitus Type 2". This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8 weeks.
What is the current status of trial NCT01358929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-04. Estimated completion is 2011-09.
What conditions does trial NCT01358929 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01358929?
The interventions under investigation include: Placebo (DRUG), RO6807952 (DRUG).
Who is sponsoring clinical trial NCT01358929?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358929 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.